cilastatin--imipenem-drug-combination has been researched along with Cystic-Fibrosis* in 3 studies
3 other study(ies) available for cilastatin--imipenem-drug-combination and Cystic-Fibrosis
Article | Year |
---|---|
Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series.
Mycobacterium abscessus is a rapidly-growing, virulent, non-tuberculous mycobacterium that causes progressive inflammatory lung damage and significant decline in lung functionin patients with cystic fibrosis. M. abscessus complex pulmonary infections are notoriously difficult to treat, and while many antibiotics are approved for children, drug allergies or intolerances can prohibit their use. Intravenous imipenem/cilastatin is among the preferred antibiotics for treatment of M. abscessus, however, its use may result in systemic toxicities including hepatic injury and gastrointestinal effects. Case reports document the successful use of inhaled imipenem/cilastatin in adult cystic fibrosis and non- cystic fibrosis patients with non- M. abscessus pulmonary infections. To our knowledge, similar evidence does not exist for pediatric patients. In this case series, we describe two pediatric patients with cystic fibrosis and previous intolerance or lack of response to standard therapies who received inhaled imipenem/cilastatin for the treatment of chronic M. abscessus infection. Topics: Administration, Inhalation; Adolescent; Cilastatin, Imipenem Drug Combination; Cystic Fibrosis; Female; Humans; Male | 2019 |
Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis.
Imipenem, a new N-formimidoyl thienamycin was given together with cilastatin to 20 patients with cystic fibrosis and pulmonary infection due to Pseudomonas aeruginosa. The antibiotic was given in short-term infusions for 9-14 days (mean 11.5) in a dose of 45-60 mg/kg body weight/day. Good clinical results were obtained in all patients with significant improvement of clinical score, pulse rate, vital capacity and FEV1.0 (P less than 0.001). Blood PO2 increased and WBC decreased significantly. A slight increase in the minimum inhibitory concentration was noted during treatment but all strains examined were fully susceptible at follow-up one month later. The peak serum concentration was significantly increased in patients receiving the high dose of imipenem, but the sputum concentration was low in all patients and there was no difference in clinical or bacteriological outcome. The plasma and urinary clearance increased with body weight and was inversely correlated to clinical score. Imipenem/cilastatin appears a good alternative for the treatment of pulmonary infections caused by P. aeruginosa in cystic fibrosis. Topics: Adolescent; Adult; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Cyclopropanes; Cystic Fibrosis; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Imipenem; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Thienamycins | 1988 |
Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Ten patients with cystic fibrosis (CF) and chronic broncho-pulmonary Pseudomonas aeruginosa infection were given imipenem/cilastatin (100 mg/kg/day) in combination with tobramycin (15 mg/kg/day). Forced vital capacity and forced expiratory volume in the first second improved significantly in nine out of ten patients, and most of the patients improved clinically. P. aeruginosa was not eradicated in any patient and resistance against imipenem developed in all patients during treatment. A concomitant increase in MIC of piperacillin and ceftazidime occurred during treatment. In-vitro bactericidal synergy of imipenem and tobramycin was noted in 57% of pretreatment isolates. Seven patients complained of adverse reactions, mainly gastrointestinal, and treatment of three patients was discontinued after 5, 8, and 12 days of therapy, because of rash or nausea and vomiting. The side effects were considered to be due to imipenem/cilastatin. Because of the rapid development of imipenem resistance despite combination therapy, the high proportion of side effects, and the risk of induction of beta-lactam resistance, imipenem/cilastatin cannot be recommended for routine treatment of CF-patients with P. aeruginosa infection. Topics: Adolescent; Adult; Anti-Bacterial Agents; Bronchopneumonia; Child; Chronic Disease; Cilastatin; Cilastatin, Imipenem Drug Combination; Cyclopropanes; Cystic Fibrosis; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imipenem; Kinetics; Male; Microbial Sensitivity Tests; Penicillin Resistance; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Thienamycins; Tobramycin | 1987 |